Teacher Retirement System of Texas Sells 2,136 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Teacher Retirement System of Texas trimmed its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 6.5% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 30,941 shares of the biopharmaceutical company’s stock after selling 2,136 shares during the period. Teacher Retirement System of Texas’ holdings in Regeneron Pharmaceuticals were worth $16,244,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Activest Wealth Management boosted its stake in shares of Regeneron Pharmaceuticals by 110.5% during the first quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 21 shares in the last quarter. Costello Asset Management INC acquired a new position in shares of Regeneron Pharmaceuticals in the first quarter worth approximately $27,000. Saudi Central Bank acquired a new position in shares of Regeneron Pharmaceuticals in the first quarter worth approximately $27,000. Colonial Trust Advisors acquired a new position in Regeneron Pharmaceuticals in the first quarter valued at approximately $32,000. Finally, SouthState Corp lifted its stake in Regeneron Pharmaceuticals by 550.0% in the first quarter. SouthState Corp now owns 52 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 44 shares during the period. Institutional investors own 83.31% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on REGN shares. Sanford C. Bernstein lifted their price target on shares of Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the company an “outperform” rating in a research report on Wednesday, August 27th. BMO Capital Markets boosted their price target on shares of Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the stock an “outperform” rating in a report on Monday, August 4th. Jefferies Financial Group increased their price target on shares of Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the company a “buy” rating in a research report on Wednesday, August 27th. Redburn Atlantic raised shares of Regeneron Pharmaceuticals to a “strong-buy” rating in a report on Thursday, August 14th. Finally, Truist Financial dropped their price objective on shares of Regeneron Pharmaceuticals from $940.00 to $812.00 and set a “buy” rating on the stock in a report on Monday, August 11th. Three research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $802.35.

Regeneron Pharmaceuticals Stock Up 11.8%

Shares of NASDAQ REGN opened at $654.48 on Wednesday. The company has a quick ratio of 3.72, a current ratio of 4.60 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $935.86. The firm’s fifty day moving average is $578.20 and its 200 day moving average is $563.34. The company has a market cap of $69.37 billion, a price-to-earnings ratio of 16.49, a PEG ratio of 1.82 and a beta of 0.31.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 EPS for the quarter, topping the consensus estimate of $9.73 by $2.10. The company had revenue of $3.75 billion for the quarter, compared to the consensus estimate of $3.57 billion. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The firm’s revenue for the quarter was up .9% on a year-over-year basis. During the same period in the previous year, the firm earned $12.46 earnings per share. On average, equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 5th. Shareholders of record on Thursday, November 20th will be given a $0.88 dividend. The ex-dividend date of this dividend is Thursday, November 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is 8.87%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.